SS Innovations International (NASDAQ: SSII) reported record second-quarter 2026 revenue of $13.9 million, a 39.4% increase from $10 million in the same period last year. The growth was driven by a 30.4% rise in installations of its SSi Mantra surgical robotic system, which reached 30 systems during the quarter. Gross profit climbed 20% to $7.1 million, with a gross margin of 50.9%, while the company posted a net loss of $2.7 million, or $0.01 per diluted share, compared with a net loss of $0.3 million a year earlier.
The company's first-half revenue surged 65.6% to $25 million, with SSi Mantra installations up 47.4% to 56 systems. As of June 30, SS Innovations had $13.6 million in cash and cash equivalents, no long-term debt, and a cumulative installed base of 224 SSi Mantra systems across 12 countries. The company reported 12,272 cumulative procedures using the SSi Mantra as of June 30, including 175 telesurgeries, and subsequently completed a robotic telesurgery spanning more than 13,600 miles between Colombia and India.
These results underscore SS Innovations' growing global footprint and its ambition to make robotic surgery affordable and accessible. The company's SSi Mantra system, along with its suite of SSi Mudra surgical instruments, supports a variety of procedures, including cardiac surgery. With a focus on cost-effectiveness and user-friendliness, the company is positioning itself as a competitive player in the surgical robotics market, which is traditionally dominated by more expensive systems.
Looking ahead, SS Innovations expects the U.S. Food and Drug Administration to complete its review of the company's 510(k) premarket notification for the SSi Mantra by the end of the first quarter of 2027. The company also believes it can obtain European Union CE marking certification by the end of 2026. These regulatory milestones are critical for expanding into major markets, and their achievement could significantly boost the company's revenue potential.
The company's progress in telesurgery is particularly noteworthy, as it demonstrates the capability to perform surgical procedures over vast distances. The recent telesurgery between Colombia and India, spanning more than 13,600 miles, highlights the potential for remote surgical expertise to reach underserved areas, aligning with SS Innovations' mission to democratize access to robotic surgery.
Despite the positive revenue growth, the company's net loss widened compared to the prior year, reflecting increased investments in research, development, and regulatory processes. However, the strong cash position and absence of long-term debt provide a solid foundation to support these initiatives.
The broader implications of SS Innovations' performance are significant for the healthcare industry. As the company expands its installed base and works toward regulatory approvals, it could challenge established players by offering a more affordable alternative. This could lead to wider adoption of robotic surgery, potentially improving patient outcomes and reducing healthcare costs.
Investors and industry observers will be watching closely as SS Innovations navigates the regulatory landscape and continues to grow its global presence. The company's ability to achieve its milestones will be crucial in determining its long-term success in the competitive surgical robotics market.
